Welcome to Multibagg AI
Log in to access personalized features
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Bearish
5
Neutral
3
Bullish
6
Bearish
5
Neutral
3
Bullish
38
Bearish
0
Neutral
0
Bullish
32
Discovery themes featuring this stock
Natco Pharma is a vertically integrated, R&D-led pharmaceutical company that develops, manufactures and markets complex finished dosage formulations (FDF) and APIs, with a strong presence in oncology and specialty generics across the US, India and multiple emerging markets; the company also invests in NCEs, cell and gene therapies to build a biotech pipeline alongside its generic business.
Q3 FY26 consolidated revenue was INR 705.4 crore with EBITDA of INR 216.8 crore and a 30.7% EBITDA margin; Q3 PAT was INR 151.3 crore and 9MFY26 PAT stands around INR 1,149.5 crore, showing NATCO Pharma has stabilized earnings despite loss of prior Revlimid tailwinds and is guiding full‑year revenue roughly around INR 4,200–4,300 crore.
Natco’s export formulations are the revenue engine, contributing nearly 60% for the quarter and 75.7% for 9MFY26, supported by strong performance from subsidiaries in Brazil, Canada, Middle East and newly acquired exposure through Adcock Ingram; this geographic diversification materially reduces single-product concentration risk and strengthens recurring revenue streams.
The company has a deep pipeline of complex ANDAs and Para‑IV opportunities in the US (30 Para IVs with >20 FTFs and 14 approvals), active semaglutide (Ozempic/Wegovy) filings for India and regulated markets, and an explicit M&A playbook targeting large acquisitions to scale international branded businesses and expand NATCO Pharma’s footprint and product mix.
NATCO Pharma has committed to biotech investments including eGenesis, NRC-2694 (Phase II approved), Cellogen, Eyestem and Stero Therapeutics, reflecting a dual strategy of near-term generics revenue plus high-risk, high-reward R&D investments that could materially change long-term growth trajectory if clinical programs succeed.
Pharmaceuticals
Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
17,066 Cr
High Risk
11.5
28.0
—
2.0
1,059.60
660.05
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stock
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Natco Pharma Ltd (NATCOPHARM) is currently trading at 997.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Natco Pharma is a vertically integrated, R&D-led pharmaceutical company that develops, manufactures and markets complex finished dosage formulations (FDF) and APIs, with a strong presence in oncology and specialty generics across the US, India and multiple emerging markets; the company also invests in NCEs, cell and gene therapies to build a biotech pipeline alongside its generic business. Q3 FY26 consolidated revenue was INR 705.4 crore with EBITDA of INR 216.8 crore and a 30.7% EBITDA margin; Q3 PAT was INR 151.3 crore and 9MFY26 PAT stands around INR 1,149.5 crore, showing NATCO Pharma has stabilized earnings despite loss of prior Revlimid tailwinds and is guiding full‑year revenue roughly around INR 4,200–4,300 crore. Natco’s export formulations are the revenue engine, contributing nearly 60% for the quarter and 75.7% for 9MFY26, supported by strong performance from subsidiaries in Brazil, Canada, Middle East and newly acquired exposure through Adcock Ingram; this geographic diversification materially reduces single-product concentration risk and strengthens recurring revenue streams. The company has a deep pipeline of complex ANDAs and Para‑IV opportunities in the US (30 Para IVs with >20 FTFs and 14 approvals), active semaglutide (Ozempic/Wegovy) filings for India and regulated markets, and an explicit M&A playbook targeting large acquisitions to scale international branded businesses and expand NATCO Pharma’s footprint and product mix. NATCO Pharma has committed to biotech investments including eGenesis, NRC-2694 (Phase II approved), Cellogen, Eyestem and Stero Therapeutics, reflecting a dual strategy of near-term generics revenue plus high-risk, high-reward R&D investments that could materially change long-term growth trajectory if clinical programs succeed.
Over the past 52 weeks, Natco Pharma Ltd has traded between a low of ₹660.05 and a high of ₹1,059.60. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Natco Pharma Ltd has a market capitalization of approximately 17,065.59. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Natco Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 11.47 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 17,065.59 Cr, Natco Pharma Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Natco Pharma Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Natco Pharma Ltd is 11.47. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The stock surged after the company received approval from India's Central Drugs Standard Control Organisation (CDSCO) to manufacture and market generic Semaglutide, a high-demand drug for type 2 diabetes.
Erdafitinib is a kinase inhibitor used for treating adult patients with locally advanced or metastatic urothelial carcinoma who have specific FGFR3 genetic alterations.
The 'Biopharma Shakti' initiative, with an outlay of 10,000 crores, aims to boost domestic production of biologics and biosimilars. This directly benefits Natco Pharma by enhancing the R&D ecosystem, improving clinical trial infrastructure, and strengthening regulatory bodies, which are crucial for Natco's complex generics and biosimilars pipeline.
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1287.40 | 21,058 Cr | 975.09 | 4.61 | 0.00 | 1.54 | 4.05 | -0.12 | |
952.80 | 17,066 Cr | 10.96 | 1.97 | 0.63 | 17.79 | 21.15 | 14.81 | |
553.50 | 13,432 Cr | 25.15 | 3.37 | 0.27 | 12.88 | 13.37 | 7.86 | |
1223.60 | 12,608 Cr | 41.14 | 6.90 | 0.73 | 17.73 | 23.48 | 15.38 | |
298.00 | 11,389 Cr | 57.11 | 3.01 | 0.00 | 10.47 | 11.28 | 4.65 | |
908.70 | 11,164 Cr | 20.54 | 3.70 | 0.55 | 17.59 | 23.34 | 14.94 | |
1550.00 | 9,420 Cr | 63.45 | 14.28 | 0.47 | 26.53 | 33.34 | 17.54 |
